OncoLens has raised $16 million in a Series B financing round

OncoLens has raised $16 million in a Series B financing round

OncoLens which is a Health Tech startup and working on cancer treatment has raised around $16 Million from Cross Border Impact Ventures and BIP Capital and also includes existing investors , SeedToB Capital and Martin Ventures.

OncoLens is one of the fastest growing company in the Inc 5000’s 2024 and has a research network and cancer treatment platform will use this amount to take its research to the next level using AI enabled clinical and workflow solutions that it provides to its customers which includes prominent names like NCIs(national cancer institutes), etc.

With its global clientele and partnerships, OncoLens has partnered with clinical development teams and has launched OncoLens Research Network in the EMEA (Europe, Middle East and Africa) area to further its trial and for getting genuine results.

Anju Mathew is the CEO and CoFounder at OncoLens and she herself has experienced the wrath of cancer in her family which motivated her to get best available treatment of cancer using latest technological advancements such as Artificial Intelligence. So, she started OncoLens which provides planning, accreditation, tumor board management, and quality improvement to patients. previously, she has served as head at McKesson’s Medical Surgical business unit and has led many successful breakthroughs and partnerships.

OncoLens has around 225+ cancer center and life science partners that helps the company to create a meaningful impact on the lives of the people.


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *